Advanced Oncology Drug Management for Cancer Care
How Avalon integrates genetic testing with oncology drug management to improve treatment precision and reduce delays.
Avalon’s Approach
Avalon’s oncology drug management program streamlines prior authorizations, standardizes testing, and aligns results with guideline-based therapies.
- Automated test authorization workflows to minimize delays
- Broad-panel next-generation sequencing (NGS) adoption to improve diagnostic accuracy and lower costs
- Clear protocols to ensure test results are available for timely treatment planning
This coordinated approach improves therapy selection, reduces costs, and supports better outcomes for cancer patients.
Proven Impact
Advanced oncology drug management, powered by genetic testing integration, offers a way to overcome these hurdles. The approach focuses on:
Expected Outcomes
Reduced Time to Treatment
From 40–60 days to as few as 10–15 days.
Improved Patient Outcomes
Through personalized therapy selection, minimizing ineffective treatments and side effects.
Significant Cost Savings
$75
saved per life year gained for every 10% increase in NGS use in NSCLC (JCO Precision Oncology, 2023).
$8.5k
PMPM savings from broad-panel testing over sequential approaches (2020 study).
Avoided waste
from inappropriate drug use due to incomplete biomarker data (44% of NSCLC patients affected).
Optimize your oncology drug management with data-driven, personalized strategies.
Partner with the leaders in diagnostic value management to transform cancer care today.